BCLI - Brainstorm Cell Therapeutics, Inc.
1.21
0 0%
Share volume: 60,121
Last Updated: 05-07-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.02%
PREVIOUS CLOSE
CHG
CHG%
$1.21
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 05-14-2024 | 08-14-2023 | 11-14-2023 | 11-14-2024 | 05-14-2024 | 08-14-2024 | 11-14-2024 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 5.151 M | 5.449 M | 6.035 M | 4.804 M | 2.474 M | 2.982 M | 3.048 M | |
| Selling general and admin | 2.227 M | 2.655 M | 2.705 M | 3.106 M | 1.513 M | 2.060 M | 2.003 M | |
| Research and development | 2.924 M | 2.794 M | 3.330 M | 1.698 M | 961.000 K | 922.000 K | 1.045 M | |
| Total expenses | 5.151 M | 5.449 M | 6.035 M | 4.804 M | 2.474 M | 2.982 M | 3.048 M | |
| 5.79% | 10.75% | -20.40% | -48.50% | 20.53% | 2.21% | |||
| Operating income | -5.151 M | -5.449 M | -6.035 M | -4.804 M | -2.474 M | -2.982 M | -3.048 M | |
| Ebit | -5.151 M | -5.449 M | -6.035 M | -5.040 M | -3.414 M | -2.571 M | -2.654 M | |
| Pretax income | -5.059 M | -5.329 M | -6.035 M | -5.131 M | -3.414 M | -2.571 M | -2.654 M | |
| 5.34% | 13.25% | -14.98% | -33.46% | -24.69% | 3.23% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -5.059 M | -5.329 M | -6.035 M | -5.578 M | -3.401 M | -2.541 M | -2.708 M | |
| -5.34% | -13.25% | 7.57% | 39.03% | 25.29% | -6.57% |
